Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Coherus Oncology, Inc. Enters $50 Million Sales Agreement for Common Stock
PRIVATEAug 28, 2026•1 day ago
Amount Raised
$50 Million
Round Type
Funding Round
Redwood CityBiotechnologyHealthcare
Investors
Leerink Partners Llc
Description
On August 28, 2026, Coherus Oncology, Inc. entered into a sales agreement with Leerink Partners LLC, allowing the company to offer and sell shares of its common stock with an aggregate offering price of up to $50 million. This agreement provides the company flexibility in raising capital without obligation to sell any specified number of shares. The arrangement allows for periodic sales through the agent to respond to market conditions
Company Information
Company
Coherus BioSciences
Location
Redwood City, California, United States
About
Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics. We are building a leading oncology company backed by in-house expertise and an established infrastructure from our diversified portfolio of FDA-approved biosimilar products.
Don't miss Coherus BioSciences's next move
Get an email the moment Coherus BioSciences raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Predictive Intelligence
Strategic
ML-powered predictions for Coherus BioSciences's next move
Redwood CityBiotechnologyHealthcare